Results 91 to 100 of about 10,600 (216)

Systematic Review of Postvaccination Ocular Adverse Events: A Comprehensive Analysis of Published Reports

Journal of Medical Virology, Volume 97, Issue 12, December 2025.
ABSTRACT Ocular adverse events following COVID‐19 vaccination are well described; however, systematic analyses of non‐COVID antiviral vaccines remain limited. This review aimed to evaluate ocular complications associated with non‐COVID antiviral immunizations, including influenza, varicella‐zoster (VZV), human papillomavirus (HPV), and hepatitis B (HBV)
Yaru Zou, Koju Kamoi, Yuan Zong, Jing Zhang, Mingming Yang, Kyoko Ohno‐Matsui   +5 more
wiley   +1 more source

Research Progress on Varicella-Zoster Virus Vaccines

Vaccines
Varicella-zoster virus (VZV) poses significant public health challenges as the etiological agent of varicella (chickenpox) and herpes zoster (HZ), given its high transmissibility and potential for severe complications.
Hongjing Liu, Lingyan Cui, Sibo Zhang, Hong Wang, Wenhui Xue, Hai Li, Yuyun Zhang, Lin Chen, Ying Gu, Tingting Li, Ningshao Xia, Shaowei Li   +11 more
doaj   +1 more source

National Trends and Disparities in Herpes Zoster Vaccination Among US Older Adults With Diabetes, 2008–2023

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 12, December 2025.
ABSTRACT Purpose To evaluate trends and disparities in herpes zoster vaccination among US older adults with diabetes. Methods Data from the 2008 to 2023 National Health Interview Survey were used. Joinpoint regression analysis was performed to analyze trends in herpes zoster vaccination.
Chun‐Tse Hung, Li‐Min Wang, Ding‐Cheng Liu, Yu‐Chien Hung   +3 more
wiley   +1 more source

Stevens-Johnson Syndrome–Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer

Journal of Investigative Medicine High Impact Case Reports, 2020
Stevens-Johnson syndrome (SJS) is a life-threating mucocutaneous reaction predominantly induced by drugs. Targeted cancer therapies such as pembrolizumab, which has been approved for the treatment of metastatic malignancy, can cause severe skin ...
Ivy Riano MD, Cagney Cristancho MD, Thomas Treadwell MD   +2 more
doaj   +1 more source

Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta‐analysis

Rheumatology &Autoimmunity, Volume 5, Issue 4, Page 285-296, December 2025.
A systematic review and meta‐analysis were conducted to review all clinical trial results of anifrolumab for treating systemic lupus erythematosus. Fourteen studies were included comprising 1322 patients and five studies were meta‐analyzed. It was found that anifrolumab 300 mg IV led to clinical improvement across composite lupus scores, cutaneous ...
Yomna W. Mahmoud, Mohamed Ramadan S., Doaa Radwan G., Mariam S. Abdulhafiz, Yassin M. El‐Shnawy, Alaa Alaa H., Sara Naser Sebie, Maryam A. Elashmawi, Husni Zahi M., Mohammad T. Abuawwad, Mohammad J. Taha, Abdulqadir J. Nashwan   +11 more
wiley   +1 more source

Lack of autoantibody production associated with cytomegalovirus infection [PDF]

, 2002
To confirm an association between cytomegalovirus (CMV) infection and the presence of antibodies to Smith (Sm), to ribonucleoprotein (RNP), and to a component of the U1 ribonucleoproteins (U1-70 kD), we measured antibodies to these protein antigens using
Adler, Stuart P., Greidinger, Eric, Hoffman, Robert, Marshall, Beth C., McPherson, Richard A.   +4 more
core   +3 more sources

Comparative Cytokine and Histology Studies on HPV and Other Viral Vaccinations: No Pathogenicity of HPV Vaccine Adjuvants

Cancer Science, Volume 116, Issue 12, Page 3309-3325, December 2025.
Anti‐HPV vaccine activists claimed that aluminum (Al) adjuvants in HPV vaccines could cause immune abnormalities, leading to neurological diseases. We evaluated the cytokine and histology profiles following administrations of HPV vaccines and other viral vaccines containing adjuvants.
Reona Shiro, Fumitaka Sato, Seiichi Omura, Ah‐Mee Park, Cong Thanh Nguyen, Ijaz Ahmad, Sandesh Rimal, Koji Kinoshita, Noriomi Matsumura, Ikuo Tsunoda   +9 more
wiley   +1 more source

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

Expert Review of Vaccines, 2018
Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications.
Nicolas Lecrenier, Pierre Beukelaers, Romulo Colindres, Desmond Curran, Carine De Kesel, Jean-Philippe De Saegher, Arnaud M Didierlaurent, Edouard Y Ledent, Johann F Mols, Tomas Mrkvan, Marie Normand-Bayle, Lidia Oostvogels, Fernanda Tavares Da Silva, Ventzislav Vassilev, Carlota Vinals, Alain Brecx   +15 more
doaj   +1 more source

Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. [PDF]

Ann Intern Med
A 2-dose series of recombinant zoster vaccine (RZV) was 97% effective against herpes zoster (HZ) in a pivotal clinical trial.To evaluate real-world effectiveness of RZV against HZ.Prospective cohort study.Four health care systems in the Vaccine Safety Datalink.Persons aged 50 years or older.The outcome was incident HZ defined by a diagnosis with an ...
Zerbo O, Bartlett J, Fireman B, Lewis N, Goddard K, Dooling K, Duffy J, Glanz J, Naleway A, Donahue JG, Klein NP.   +10 more
europepmc   +3 more sources

Three-dimensional normal human neural progenitor tissue-like assemblies: A model of persistent Varicella-Zoster virus infection [PDF]

, 2013
Varicella-zoster virus (VZV) is a neurotropic human alphaherpesvirus that causes varicella upon primary infection, establishes latency in multiple ganglionic neurons, and can reactivate to cause zoster.
Cohrs, Randall J., Goodwin, Thomas J., Kaufer, Benedikt B., McCarthy, Maureen, Osterrieder, Nikolaus   +4 more
core   +1 more source